You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
10 July 2024
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
14 March 2024
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
23 November 2022
HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
12 May 2022
HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
30 March 2022
HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors
4 November 2021
HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences